Literature DB >> 17001318

The kinase-inhibitory domain of p21-activated kinase 1 (PAK1) inhibits cell cycle progression independent of PAK1 kinase activity.

M Thullberg1, A Gad, A Beeser, J Chernoff, S Strömblad.   

Abstract

p21-activated kinase 1 (PAK1) is a mediator of downstream signaling from the small GTPases Rac and Cdc42. In its inactive state, PAK1 forms a homodimer where two kinases inhibit each other in trans. The kinase inhibitory domain (KID) of one molecule of PAK1 binds to the kinase domain of its counterpart and keeps it inactive. Therefore, the isolated KID of PAK1 has been widely used to specifically inhibit and study PAK function. Here, we show that the isolated KID induced a cell cycle arrest with accumulation of cells in the G1 phase of the cell cycle with an inhibition of cyclin D1 and D2 expression. This cell cycle arrest required the intact KID and was also induced by a mutated KID unable to block PAK1 kinase activity. Furthermore, the KID-induced cell cycle arrest could not be rescued by the expression of a constitutively active PAK1-T423E mutant, concluding that this arrest occurs independently of PAK1 kinase activity. Our results suggest that PAK1 through its KID inhibits cyclin D expression and thereby enforces a cell cycle arrest. Our results also call for serious precaution in the use of KID to study PAK function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17001318     DOI: 10.1038/sj.onc.1209983

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

Review 1.  PAK1 as a therapeutic target.

Authors:  Julia V Kichina; Anna Goc; Belal Al-Husein; Payaningal R Somanath; Eugene S Kandel
Journal:  Expert Opin Ther Targets       Date:  2010-07       Impact factor: 6.902

2.  Identification of phosphorylation sites in betaPIX and PAK1.

Authors:  Mark W Mayhew; Erin D Jeffery; Nicholas E Sherman; Kristina Nelson; Joy M Polefrone; Stephen J Pratt; Jeffrey Shabanowitz; J Thomas Parsons; Jay W Fox; Donald F Hunt; Alan F Horwitz
Journal:  J Cell Sci       Date:  2007-11-15       Impact factor: 5.285

3.  Oncogenic H-Ras V12 promotes anchorage-independent cytokinesis in human fibroblasts.

Authors:  Minna Thullberg; Annica Gad; Sylvie Le Guyader; Staffan Strömblad
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-11       Impact factor: 11.205

4.  An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase.

Authors:  Sean W Deacon; Alexander Beeser; Jami A Fukui; Ulrike E E Rennefahrt; Cynthia Myers; Jonathan Chernoff; Jeffrey R Peterson
Journal:  Chem Biol       Date:  2008-04

Review 5.  PAK signalling during the development and progression of cancer.

Authors:  Maria Radu; Galina Semenova; Rachelle Kosoff; Jonathan Chernoff
Journal:  Nat Rev Cancer       Date:  2014-01       Impact factor: 60.716

6.  Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion.

Authors:  Samantha K McCarty; Motoyasu Saji; Xiaoli Zhang; David Jarjoura; Alfredo Fusco; Vasyl V Vasko; Matthew D Ringel
Journal:  Endocr Relat Cancer       Date:  2010-10-29       Impact factor: 5.678

7.  PAK1-Nck regulates cyclin D1 promoter activity in response to prolactin.

Authors:  Jing Tao; Peter Oladimeji; Leah Rider; Maria Diakonova
Journal:  Mol Endocrinol       Date:  2011-06-30

Review 8.  Rheostatic signaling by CD44 and hyaluronan.

Authors:  Ellen Puré; Richard K Assoian
Journal:  Cell Signal       Date:  2009-01-13       Impact factor: 4.315

9.  Use of a decoy peptide to purify p21 activated kinase-1 in cardiac muscle and identification of ceramide-related activation.

Authors:  Yunbo Ke; R John Solaro
Journal:  Biologics       Date:  2008-12

10.  Do PAKs make good drug targets?

Authors:  Zhuo-Shen Zhao; Ed Manser
Journal:  F1000 Biol Rep       Date:  2010-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.